| Insider | Role | Shares | Value | Buys | Sells |
|---|---|---|---|---|---|
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
| Insider | Role | Shares | Value | Buys | Sells |
|---|---|---|---|---|---|
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
Director
1 company
Verwiel Frank serves as a Director at NTLA. Across recent SEC filings that breaks down to 0 buys and 1 sell. Those positions are worth an estimated $422K at current prices.
The biggest single holding is NTLA (~$422K) as Director. The recent filings there lean toward selling, a net 1,505 shares.
| Date | Ticker | Role | Type | Shares | Price | Value | Chg% | 3M | 12M | SEC |
|---|---|---|---|---|---|---|---|---|---|---|
| Jun 17, 2024 | NTLA Intellia Therapeutics, Inc. | Director | Sell | 1,505 | $25.00 | $37,625.00 | -7.7% | -14.5% | -61.9% |